Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $15.39M, compared with -$35.14M a year earlier. Trailing-twelve-month net change in cash was $35.93M. Over 3 fiscal years it compounded at +8.8% a year.
Context
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near $15.39M or moves back toward the trailing-twelve-month quarterly average of $8.98M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (14.59M) USD
- Year-over-year change
- -128.1%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.59M) | -128.1% |
| FY2024 | 2024-12-31 | 51.91M | +991.2% |
| FY2023 | 2023-12-31 | (5.82M) | +48.5% |
| FY2022 | 2022-12-31 | (11.32M) | — |
Net Change in Cash vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 net change in cash of $35.93M is the 3rd largest of the 11 companies compared; the peer median is $357K.
- Its year-over-year change of +89.5% is the 5th highest of 11, against a peer median of +26.1%.
- Over three fiscal years its annual growth of +8.8% compares with a peer median of +0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $100M | -769.9% | +42.0% | 169491.5% | |
ZURAZura Bio Limited | LTM Mar 2026 | $55.03M | -31.9% | — | — |
| LTM Mar 2026 | $35.93M | +89.5% | +8.8% | — | |
| LTM Mar 2026 | $27.89M | +253.0% | — | 98.8% | |
| LTM Mar 2026 | $27.12M | +568.0% | +19.1% | 12051.1% | |
| LTM Mar 2026 | $25.29M | +542.2% | -17.4% | 36.5% | |
| LTM Mar 2026 | $18.61M | -347.9% | -40.1% | — | |
| LTM Mar 2026 | $17.36M | -13.1% | -72.2% | 155.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $11.75M | +1066.8% | +102.1% | — |
| LTM Mar 2026 | $7.71M | +65.2% | +43.6% | 10.8% | |
| LTM Mar 2026 | $6.99M | -54.0% | -65.1% | 50.5% | |
| Peer median (excluding AARD) | $357K | +26.1% | +0.8% | 98.8% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Depreciation & Amortization | 110K | 97K | 16K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 412K | 313K | 439K | 3.95M |
| Change in Working Capital | (1.31M) | (81K) | 1.57M | 356K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 31K | 776K | 798K | 239K |
| Other Working Capital | (1.34M) | (857K) | 775K | 117K |
| Other Non-Cash Items | 3.81M | 1.06M | 473K | 421K |
| Operating Cash Flow | (10.54M) | (5.82M) | (18.09M) | (54.17M) |
| Capital Expenditures | 0 | 0 | (109K) | (95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (11.89M) | (129.6M) |
| Sales of Investments | 0 | 0 | 0 | 80.03M |
| Other Investing Activities | (1M) | 0 | 0 | 0 |
| Investing Cash Flow | (1M) | 0 | (12M) | (49.67M) |
| Debt Repayment | (1M) | 0 | 0 | 0 |
| Common Stock Issued | 225K | 0 | 332K | 89.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1M | 0 | (3.34M) | 0 |
| Financing Cash Flow | 225K | 0 | 81.99M | 89.25M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.32M) | (5.82M) | 51.91M | (14.59M) |
| Free Cash Flow | (10.54M) | (5.82M) | (18.2M) | (54.27M) |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.